In a groundbreaking partnership, the American Cancer Society (ACS) and Yosemite, an oncology-focused venture capital firm, have awarded over $6 million in research grants. These grants are set to accelerate innovations in cancer research, particularly in immuno-oncology and Artificial Intelligence (AI) applications in cancer care. This collaboration could change the landscape of cancer treatment and prevention, opening new doors for early detection and advanced therapies.

Designed to foster pioneering research at institutions nationwide, the Yosemite-ACS Award reflects Yosemite's commitment to a science-first approach, blending unrestricted grantmaking with traditional funding methods. These grants bolster a vibrant ecosystem of research aligned with Yosemite and ACS's shared mission to eradicate cancer for all.

Dr. William Dahut, Chief Scientific Officer at the American Cancer Society, emphasized, "The American Cancer Society is proud to partner with Yosemite to advance innovative research. These studies leverage novel approaches in molecular research, immunotherapy, and AI to propel cancer therapies and enhance the patient experience."

Anna Darbyshire, Chief Operating Officer at Yosemite, underscored the strategic significance of their flexible capital strategy, stating, "Investing in initiatives like the Yosemite-ACS Award is integral to our mission of driving cancer research forward. Collaborating with a globally renowned organization and the largest private funder of cancer research in the U.S., our hybrid investment model enables us to accelerate cutting-edge scientific discoveries at all stages of development, aiming to render cancer non-lethal within our lifetimes."

The grant recipients encompass a diverse cohort of researchers, ranging from early-career scientists to internationally recognized interdisciplinary experts, united in advancing cancer research. Projects awarded in 2024 include accelerating immunotherapy effectiveness, elucidating molecular immunity mechanisms, and harnessing AI to enhance patient care and healthcare accessibility.

Looking ahead, the Yosemite-ACS Award will expand in 2025, broadening the Request for Proposals (RFP) process to sustain funding for transformative cancer research and deliver immediate impact to the scientific community.